Brian Clevinger is a founder and managing director of Prolog.

Brian has 20 years of experience in all phases of commercial technology development. He currently focuses on drug delivery, aesthetic materials and devices, and plant biotechnology. Previously, following an academic career in a tenured position at Washington University in St. Louis, he learned the art of investing at an affiliate of Alafi Capital and then served as founding CEO of a vaccine delivery company. Brian holds a doctorate in immunology from Indiana University and has completed his postdoctoral fellowship at Washington University.

Selected Portfolio Companies
-----------------------------------------------------------------------------------------
AirXpanders       APT Therapeutics         Travanti
Altheus              Chlorogen                   ZyStor